Acute optic neuritis - Pipeline Insight, 2021
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Acute optic neuritis - Pipeline Insight, 2021,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Acute optic neuritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Acute optic neuritis: Overview
Optic neuritis is an inflammatory disease of the optic nerve and is frequently the presenting sign of multiple sclerosis. These patients commonly experience pain on eye movement and then suddenly have a major loss in visual acuity, usually in one eye. The blindness often resolves in 6-8 weeks. Six months after the episode of blindness, more than half of the patients have some visual changes, including deficits in color vision, contrast sensitivity, and light brightness. The current treatment is steroids, which reduce the period of visual acuity loss but have little or no effect on the preventing damage to contrast vision.
'Acute optic neuritis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute optic neuritis pipeline landscape is provided which includes the disease overview and Acute optic neuritis treatment guidelines. The assessment part of the report embraces, in depth Acute optic neuritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute optic neuritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Acute optic neuritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute optic neuritis Emerging Drugs
Further product details are provided in the report……..
Acute optic neuritis: Therapeutic Assessment
This segment of the report provides insights about the different Acute optic neuritis drugs segregated based on following parameters that define the scope of the report, such as:
Acute optic neuritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute optic neuritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute optic neuritis drugs.
Acute optic neuritis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Acute optic neuritis - Pipeline Insight, 2021,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Acute optic neuritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Acute optic neuritis: Overview
Optic neuritis is an inflammatory disease of the optic nerve and is frequently the presenting sign of multiple sclerosis. These patients commonly experience pain on eye movement and then suddenly have a major loss in visual acuity, usually in one eye. The blindness often resolves in 6-8 weeks. Six months after the episode of blindness, more than half of the patients have some visual changes, including deficits in color vision, contrast sensitivity, and light brightness. The current treatment is steroids, which reduce the period of visual acuity loss but have little or no effect on the preventing damage to contrast vision.
'Acute optic neuritis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute optic neuritis pipeline landscape is provided which includes the disease overview and Acute optic neuritis treatment guidelines. The assessment part of the report embraces, in depth Acute optic neuritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute optic neuritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Acute optic neuritis R&D. The therapies under development are focused on novel approaches to treat/improve Acute optic neuritis.
This segment of the Acute optic neuritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute optic neuritis Emerging Drugs
- BN201: Bionure
- ST266: Noveome
Further product details are provided in the report……..
Acute optic neuritis: Therapeutic Assessment
This segment of the report provides insights about the different Acute optic neuritis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Acute optic neuritis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Acute optic neuritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute optic neuritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute optic neuritis drugs.
Acute optic neuritis Report Insights
- Acute optic neuritis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Acute optic neuritis drugs?
- How many Acute optic neuritis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute optic neuritis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute optic neuritis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Acute optic neuritis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Bionure
- Noveome
- Lipocure
- BN201
- ST-266
- LC200
Introduction
Executive Summary
Acute optic neuritis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Acute optic neuritis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Acute optic neuritis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Acute optic neuritis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
BN201: Bionure
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ST-266: Noveome
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Acute optic neuritis Key Companies
Acute optic neuritis Key Products
Acute optic neuritis- Unmet Needs
Acute optic neuritis- Market Drivers and Barriers
Acute optic neuritis- Future Perspectives and Conclusion
Acute optic neuritis Analyst Views
Acute optic neuritis Key Companies
Appendix
Executive Summary
Acute optic neuritis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Acute optic neuritis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Acute optic neuritis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Acute optic neuritis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
BN201: Bionure
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ST-266: Noveome
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Acute optic neuritis Key Companies
Acute optic neuritis Key Products
Acute optic neuritis- Unmet Needs
Acute optic neuritis- Market Drivers and Barriers
Acute optic neuritis- Future Perspectives and Conclusion
Acute optic neuritis Analyst Views
Acute optic neuritis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Acute optic neuritis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Acute optic neuritis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Acute optic neuritis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Acute optic neuritis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products